2001
Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy
Holman R, Paddock C, Curns A, Krebs J, McQuiston J, Childs J. Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy. The Journal Of Infectious Diseases 2001, 184: 1437-1444. PMID: 11709786, DOI: 10.1086/324372.Peer-Reviewed Original ResearchConceptsRisk factorsFatal Rocky Mountain Spotted FeverRocky Mountain Spotted FeverOnset of symptomsCase fatality rateTetracycline-class antibioticsPrimary therapyClinical characteristicsOlder patientsAppropriate therapyRMSF casesNonfatal casesNational surveillanceHigh riskSpotted FeverPatientsEffective antibioticsTherapyDeathFeverAntibioticsTreatmentSymptomsFactorsDisease
1998
Causes, Costs, and Estimates of Rabies Postexposure Prophylaxis Treatments in the United States
Krebs J, Long-Marin S, Childs J. Causes, Costs, and Estimates of Rabies Postexposure Prophylaxis Treatments in the United States. Journal Of Public Health Management And Practice 1998, 4: 56-62. PMID: 10187067, DOI: 10.1097/00124784-199809000-00009.Peer-Reviewed Original Research
1996
Mass human exposure to rabies in New Hampshire: exposures, treatment, and cost.
Noah D, Smith M, Gotthardt J, Krebs J, Green D, Childs J. Mass human exposure to rabies in New Hampshire: exposures, treatment, and cost. American Journal Of Public Health 1996, 86: 1149-51. PMID: 8712277, PMCID: PMC1380629, DOI: 10.2105/ajph.86.8_pt_1.1149.Peer-Reviewed Original ResearchConceptsTreatment recipientsSystemic adverse reactionsMass human exposureImmune globulinMedian ageTreatment guidelinesPostexposure treatmentRabies exposureSystemic reactionsAdverse reactionsLower riskLocal reactionsCommon exposureRecipientsHuman exposureTreatmentPrevious reportsExposureRabiesResult of contactVaccinePersonsGlobulin